Our computational-experimental pipeline prioritizes four biomarkers (NAMPT, NFKBIA, SLC40A1, PRKCQ) that stratify pneumonia risk and predict targeted drugs for therapeutic repurposing. Here, NFKBIA is linked to susceptibility to pneumonia measurement.